<DOC>
	<DOCNO>NCT00108615</DOCNO>
	<brief_summary>Subjects impair glucose tolerance randomize receive pioglitazone metformin 10 week . Measurements insulin sensitivity , body composition , glucose tolerance , muscle lipid accumulation perform . Adipose tissue muscle biopsy perform . The goal study determine whether lipotoxiciy impair glucose tolerance ameliorate pioglitazone .</brief_summary>
	<brief_title>Effects Insulin Sensitizers Subjects With Impaired Glucose Tolerance</brief_title>
	<detailed_description>The progression type 2 diabetes represent evolution , result vicious cycle glucotoxicity lipotoxicity act reduce insulin secretion insulin action . Lipotoxicity new concept , refers overaccumulation lipid non-adipose tissue reflect increase free fatty acid delivery . Increased fat content skeletal muscle islet cell associate insulin resistance impair pancreatic -cell function respectively animal model . Whether lipotoxicity link obesity diabetes , human , whether reduce intracellular fat content improve insulin secretion sensitivity human know . In study , focus obese subject impair glucose tolerance ( IGT ) yet develop glucose toxicity . We examine insulin secretion , insulin action , hepatic glucose production , muscle lipid metabolism response two insulin sensitizer two different mode action . We propose thiazolidinediones improve cell function reverse lipotoxicity reflective reduce muscle lipid accumulation . Hypothesis 1 . In subject impaired glucose tolerance , insulin resistant also insulin secretory defect , thiazolidinediones , biguanides , improve cell function . Hypothesis 2 . In subject impaired glucose tolerance , thiazolidinediones , biguanides , decrease accumulation fat non-adipose tissue include muscle , pancreas , liver myocardium . Specific Aim 1 . Fifty subject impair glucose tolerance recruit randomized pioglitazone metformin treatment Specific Aim 2. cell function evaluate measuring change acute insulin response glucose non-glucose secretagogues subject IGT compare response treatment pioglitazone versus metformin . Specific Aim 3 . The muscle fat content evaluate surrogate measure lipotoxicity overaccumulation fat non-adipose tissue . From muscle biopsy specimen , measure amount intramyocellular triglyceride treatment pioglitazone versus metformin . Specific Aim 4 . Adipose tissue cytokine expression associate change muscle lipid accumulation .</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Impaired glucose tolerance Body mass index ( BMI ) 2838 Heart disease Renal disease Liver disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>